Alnylam Pharmaceuticals
ALNY
#457
Rank
โ‚น4.654 T
Marketcap
โ‚น35,229
Share price
-5.68%
Change (1 day)
63.35%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น15.44

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น8.15. In 2023 the company made an earnings per share (EPS) of -โ‚น319.54 an increase over its 2022 EPS that were of -โ‚น840.93.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น15.44
2023-โ‚น319.54-62%
2022-โ‚น840.9329.03%
2021-โ‚น651.74-3.36%
2020-โ‚น674.37-8.48%
2019-โ‚น736.837.67%
2018-โ‚น684.3339.74%
2017-โ‚น489.7112.94%
2016-โ‚น433.5938.84%
2015-โ‚น312.29-32.88%
2014-โ‚น465.27259.44%
2013-โ‚น129.44-31.25%
2012-โ‚น188.28

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-โ‚น113.15-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น3,932 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น248.02-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น21.72-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น66.08-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น666.23 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น335.44 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚น57.03 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel